Showing results (1731-1740 of 1,960) with videos related to

Sort By:
Pageof 196
Cancer Immunology, Immunotherapy : CII|July 2, 2013
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosisBridget Charbonneau, Alice H Wang, Matthew J Maurer, et al.
Molecular Biology and Evolution|July 24, 2020
Eukaryote-Conserved Methylarginine Is Absent in Diplomonads and Functionally Compensated in GiardiaSamantha J Emery-Corbin, Joshua J Hamey, Brendan R E Ansell, et al.
Blood Cancer Journal|May 3, 2022
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohortsSanjal H Desai, Levi Pederson, Betsy LaPlant, et al.
Heart (British Cardiac Society)|August 10, 2017
Disease understanding in patients newly diagnosed with atrial fibrillationBrystana G Kaufman, Sunghee Kim, Karen Pieper, et al.
Angewandte Chemie (International Ed. in English)|July 12, 2012
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivoMuthusamy Jayaraman, Steven M Ansell, Barbara L Mui, et al.
The Lancet. Haematology|April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialRajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
British Journal of Haematology|May 30, 2018
Human Pegivirus infection and lymphoma risk and prognosis: a North American studyAngelo Fama, Jinhua Xiang, Brian K Link, et al.
Blood Cancer Journal|March 27, 2021
Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failureJennifer J Gile, Camden L Lopez, Gordon J Ruan, et al.
Hematological Oncology|August 28, 2021
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg typeRobert M Kraft, Stephen M Ansell, Jose C Villasboas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 StudyRadhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, et al.
Pageof 196